CN114129660A - Special calcium tablet for perimenopausal women and preparation method thereof - Google Patents
Special calcium tablet for perimenopausal women and preparation method thereof Download PDFInfo
- Publication number
- CN114129660A CN114129660A CN202010917209.XA CN202010917209A CN114129660A CN 114129660 A CN114129660 A CN 114129660A CN 202010917209 A CN202010917209 A CN 202010917209A CN 114129660 A CN114129660 A CN 114129660A
- Authority
- CN
- China
- Prior art keywords
- parts
- calcium
- perimenopausal women
- tablet
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 239000011575 calcium Substances 0.000 title claims abstract description 55
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 18
- 239000006228 supernatant Substances 0.000 claims abstract description 17
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims abstract description 9
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 9
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 9
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 9
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 7
- 244000197580 Poria cocos Species 0.000 claims abstract description 7
- 229940069978 calcium supplement Drugs 0.000 claims abstract description 7
- 241000628997 Flos Species 0.000 claims abstract description 6
- 235000003332 Ilex aquifolium Nutrition 0.000 claims abstract description 6
- 235000002296 Ilex sandwicensis Nutrition 0.000 claims abstract description 6
- 235000002294 Ilex volkensiana Nutrition 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 5
- 241000756042 Polygonatum Species 0.000 claims abstract description 4
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 4
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 3
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 3
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 3
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 3
- 241000219784 Sophora Species 0.000 claims abstract description 3
- 210000002421 cell wall Anatomy 0.000 claims abstract description 3
- 235000013305 food Nutrition 0.000 claims abstract description 3
- 238000012545 processing Methods 0.000 claims abstract description 3
- 238000009475 tablet pressing Methods 0.000 claims abstract description 3
- 238000000605 extraction Methods 0.000 claims description 17
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 238000002386 leaching Methods 0.000 claims description 5
- 239000011344 liquid material Substances 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 238000005516 engineering process Methods 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 244000046146 Pueraria lobata Species 0.000 abstract description 5
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 5
- 235000018927 edible plant Nutrition 0.000 abstract description 4
- 206010006956 Calcium deficiency Diseases 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 208000001132 Osteoporosis Diseases 0.000 description 9
- 230000037182 bone density Effects 0.000 description 9
- 238000012795 verification Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 238000000874 microwave-assisted extraction Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 235000001188 Peltandra virginica Nutrition 0.000 description 2
- 241001633680 Polygonatum odoratum Species 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 210000002436 femur neck Anatomy 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000605447 Anemarrhena Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 241000157491 Morinda Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000157352 Uncaria Species 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229930191283 anemarrhena Natural products 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000007215 black sesame Nutrition 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 108010052008 colla corii asini Proteins 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 235000017524 noni Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention determines the core gene target of calcium deficiency of perimenopausal women by using vital big data, and obtains a medicinal and edible plant formula for calcium supplement of the perimenopausal women by using network pharmacology big data screening, wherein the medicinal and edible plant formula is prepared from the following raw materials in parts by weight: 5-40 parts of rhizoma polygonati, 5-30 parts of sophora flower, 2-30 parts of wolfberry fruit, 2-30 parts of polygonatum, 2-20 parts of poria cocos, 2-30 parts of chlorella, 5-30 parts of kudzu root, 5-20 parts of maca and 2-20 parts of broadleaf holly leaf, and the food raw materials containing 800mg of calcium of 400-mangnolia officinalis are matched for use and prepared according to the following method: s1 micronizing radix Puerariae, maca, rhizoma Polygonati Odorati, Poria, and Folum Ilicis, breaking cell wall, and extracting functional components; centrifuging the S2 extract to obtain supernatant; s3 concentrating the supernatant, mixing with calcium material, flos Sophorae Immaturus, fructus Lycii, and Chlorella superfine powder; s4 granulating, aseptically processing, and preparing the special calcium tablet for perimenopausal women by a standard tablet pressing process. The calcium tablet is designed according to life big data, is prepared from medicinal and edible plant raw materials, and has simple preparation method.
Description
Technical Field
The invention relates to a special calcium tablet for perimenopausal women and a preparation method thereof.
Background
Perimenopause is a period before and after menopause of women, is a normal physiological change period, is mainly caused by ovarian function decline, and has endocrine, biological and clinical characteristics related to menopause, and generally begins from about 45 years old to 1 year after menopause. Osteoporosis (OP) in perimenopausal women is mainly associated with a decline in ovarian function and a decline in estrogen levels in women during this period, a skeletal disease characterized by a decrease in systemic bone mass and destruction of the bone microstructure, which in turn leads to increased bone fragility and increased risk of fracture, due to a variety of causes.
At present, sex Hormone Replacement Therapy (HRT) is the first-line therapy for preventing and treating perimenopausal osteoporosis, but has the risk of increasing the incidence rate of cardiovascular and cerebrovascular diseases, invasive breast cancer, venous thrombosis diseases and the like, so that the clinical application of the HRT is limited.
The other method for preventing and treating perimenopausal osteoporosis is calcium supplement, but the current calcium supplement products supplement calcium and supplement calcium, and exogenous calcium is only added under the condition that the absorption and transformation mechanism of calcium is not completely understood, and other necessary conditions of calcium absorption are neglected, so that the absorption amount of calcium is far less than the daily requirement of calcium, and the situation that only calcium is not absorbed is caused.
Chinese patent CN201210422523.6 discloses a calcium preparation, its preparation method and application, the formulation is composed of calcium salt, vitamin D, vitamin K, mannitol and glucose. Chinese patent CN200910082672.0 discloses a micro-emulsion calcium preparation, a preparation method and application thereof, wherein a micro-emulsion structure is used as a carrier of a calcium source, and vitamins, lecithin and sorbitol are used in a matching manner. The calcium supplement formulas and products are only designed from the calcium absorption perspective, and the fundamental reason that the perimenopausal women cause bone metabolism abnormality due to endocrine imbalance is not specifically considered. Calcium is not supplemented aiming at the physiological characteristics of the perimenopausal women, and the osteoporosis problem of the perimenopausal women cannot be fundamentally solved. Such as: chinese patent CN201410634969.4 discloses a Chinese medicinal composition for treating perimenopausal syndrome, which comprises rehmannia root, anemarrhena rhizome, phellodendron bark, glossy privet fruit, epimedium, morinda root, white peony root, tuber fleeceflower stem, salvia miltiorrhiza and uncaria; chinese patent CN201610839832.1 discloses a cornu Cervi Pantotrichum powder for the treatment of perimenopausal syndrome, which is prepared from cornu Cervi Pantotrichum, parched rhizoma Dioscoreae, and colla Corii Asini; chinese patent CN201510998572.8 discloses an ointment for conditioning perimenopausal syndrome and a preparation method thereof, wherein the formula comprises donkey-hide gelatin, tortoise-shell glue, Chinese yam, medlar, mulberry, kudzu root, rhizoma polygonati, cinnamon, tuckahoe, spina date seed, rhizoma anemarrhenae, liquorice, walnut kernel, black sesame, rock candy and yellow wine;
the existing traditional Chinese medicine patents are all patents aiming at perimenopausal syndrome, but perimenopausal osteoporosis cannot be equivalently prevented and treated, the optimum medicine formula cannot be screened from a molecular mechanism if the specific mechanism of the perimenopausal osteoporosis cannot be effectively aimed at, and the effectiveness cannot be influenced necessarily due to the lack of scientificity.
Disclosure of Invention
Aiming at the defects of calcium supplement for the perimenopausal women, the invention determines the core gene target of the calcium deficiency of the perimenopausal women by using life big data, and obtains a medicinal and edible plant composition for calcium supplement for the perimenopausal women by using network pharmacology big data screening: 400-800mg calcium, 5-40 parts of rhizoma polygonati, 5-30 parts of sophora flower, 2-30 parts of wolfberry fruit, 2-30 parts of polygonatum, 2-20 parts of poria cocos, 2-30 parts of chlorella, 5-30 parts of radix puerariae, 5-20 parts of maca and 2-20 parts of broadleaf holly leaf are prepared according to the following method: s1 micronizing radix Puerariae, maca, rhizoma Polygonati Odorati, Poria, and Folum Ilicis, breaking cell wall, and extracting functional components; centrifuging the S2 extract to obtain supernatant; s3 concentrating the supernatant, mixing with calcium material, flos Sophorae Immaturus, fructus Lycii, and Chlorella superfine powder; s4 granulating, aseptically processing, and preparing the special calcium tablet for perimenopausal women by a standard tablet pressing process.
Preferably, the agitation leaching parameters are: the liquid-material ratio is 5-12, the extraction temperature is 90-boiling, the extraction time is 0.5-2 hours, and the extraction times are 1-2 times.
Preferably, the extracting solution is phosphate solution, so as to maintain the pH value of the extracting solution stable and adjust the calcium-phosphorus ratio to improve the calcium absorption and utilization efficiency.
Preferably, the supernatant is obtained using a continuous centrifugation technique, preferably a tube centrifuge.
Preferably, the calcium is a calcium-containing material as specified in food safety laws.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A special calcium tablet for perimenopausal women and a preparation method thereof, specifically comprises the following steps: s1 mixing the following raw materials: 5 parts of kudzu root, 5 parts of maca, 5 parts of rhizoma polygonati, 2 parts of polygonatum odoratum, 2 parts of poria cocos and 2 parts of broadleaf holly leaf are subjected to superfine grinding and then mixed according to the following proportion; s2 stirring and leaching, wherein the specific parameters are as follows: 0.1M phosphate solution (pH7.0), liquid-material ratio of 5, extraction temperature of 90 deg.C, extraction time of 0.5 hr, extraction frequency of 2 times, and microwave-assisted extraction to accelerate dissolution, wherein the extraction adopts tubular centrifuge to obtain supernatant, and rotation speed of 16000 rpm takes supernatant; s3 vacuum concentrating the supernatant, mixing with calcium carbonate material containing 600mg calcium, 5 parts of flos Sophorae Immaturus, 2 parts of fructus Lycii, and 2 parts of Chlorella micropowder; s4 granulating according to standard granulating process, performing aseptic treatment, and preparing calcium tablet for perimenopausal women according to tablet standard process.
Example 2
A special calcium tablet for perimenopausal women and a preparation method thereof, specifically comprises the following steps: s1 mixing the following raw materials: 30 parts of kudzuvine root, 20 parts of maca, 40 parts of rhizoma polygonati, 30 parts of fragrant solomonseal rhizome, 20 parts of tuckahoe and 20 parts of broadleaf holly leaf are subjected to superfine grinding and then mixed according to the following proportion; s2 stirring and leaching, wherein the specific parameters are as follows: 0.2M phosphate solution (pH7.0), liquid-material ratio of 12, boiling extraction at extraction temperature, extraction time of 2 hours, extraction times of 1 time, accelerated dissolution by using microwave-assisted extraction technology, obtaining supernatant by using a tubular centrifuge, and taking the supernatant at a rotation speed of 16000 rpm; s3 vacuum concentrating the supernatant, mixing with superfine powder of 800mg calcium chloride, 30 parts flos Sophorae Immaturus, 30 parts fructus Lycii, and 30 parts Chlorella; s4 granulating according to standard granulating process, performing aseptic treatment, and preparing calcium tablet for perimenopausal women according to tablet standard process.
Example 3
A special calcium tablet for perimenopausal women and a preparation method thereof, specifically comprises the following steps: s1 mixing the following raw materials: 10 parts of kudzu root, 10 parts of maca, 10 parts of rhizoma polygonati, 10 parts of polygonatum odoratum, 10 parts of poria cocos and 10 parts of broadleaf holly leaf are subjected to superfine grinding and then mixed according to the following proportion; s2 stirring and leaching, wherein the specific parameters are as follows: extracting with pure water at a liquid-material ratio of 5, an extraction temperature of 90 deg.C, an extraction time of 1 hr, and an extraction frequency of 2 times, accelerating dissolution by using microwave-assisted extraction technology, obtaining supernatant by using a tubular centrifuge, and obtaining supernatant at a rotation speed of 16000 rpm; s3 vacuum concentrating the supernatant, mixing with calcium carbonate containing 400mg calcium and calcium phosphate raw material containing 400mg calcium, 10 parts of flos Sophorae Immaturus, 10 parts of fructus Lycii, and 10 parts of Chlorella micropowder; s4 granulating according to standard granulating process, performing aseptic treatment, and preparing calcium tablet for perimenopausal women according to tablet standard process.
Clinical validation
Example 1, example 2, and example 3 were all clinically validated according to the following methods:
method (A)
Inclusion criteria for 1 case
Female, age 41-60 years old; the diagnosis standard of perimenopausal syndrome is met; the patients were tested voluntarily, and the medicine was taken on time and the doctor was given a double-visit at regular intervals.
2 exclusion criteria
Those under the age of 41 or over the age of 60; combined with primary diseases such as liver and kidney, cardiovascular and cerebrovascular diseases, hemopoietic disorder and the like, and psychonoses; bilateral ovariectomy, ovarian tumor and premature ovarian failure; essential hypertension, essential hypotension and chronic anemia; those who have used sex hormone drugs within approximately 3 months; if the medicine is not taken according to the regulation, the curative effect can not be judged; insufficient data and the like affecting the judgment of curative effect or safety.
3 clinical verification
Statistics is carried out on osteoporosis cases of perimenopausal women, and 20 cases are respectively treated by taking a calcium tablet alone as a control group and taking the calcium tablet of the embodiment as a verification group. The taking method comprises the following steps: a calcium tablet is taken 3 times a day according to the instruction; the calcium tablet of the embodiment of the invention is 2 tablets per time and 3 times a day; the administration is continued for 3 months.
Bone density measurement: the bone density of lumbar vertebrae L2-4 and left femoral neck Wards triangle of 2 groups of patients was measured by a dual-energy X-ray bone density measuring instrument before and after administration (3 months later).
The statistical method adopts SPSS 20.0 statistical software to perform data analysis, the measurement data is expressed by x +/-s, the comparison adopts t test, and the counting data comparison adopts x 2 test. P <0.05 indicates that the difference is statistically significant.
(II) verification result
Example 1 comparison of bone Density before and after administration (g/cm)3,Mean±SD)
Example 2 comparison of bone Density before and after administration (g/cm)3,Mean±SD)
Example 3 comparison of bone Density before and after administration (g/cm)3,Mean±SD)
The clinical verification result shows that: after the control group and the verification group are taken for 3 months, the bone density of lumbar vertebra and femoral neck is improved to different degrees. The calcium tablets of the invention have better effect on relieving perimenopausal osteoporosis than the calcium preparation of the control group by verifying that the bone density of the group is improved higher than that of the control group in each example, wherein the water average for improving the bone density of the verification group of the example 2 is higher than that of the examples 1 and 3, and the example 2 is a better formula ratio and a preparation process of the calcium tablets of the invention.
Any combination of the summary of the invention and the detailed description of the invention section above, including the description of the invention, is not intended to be limiting in any way and does not describe all aspects of the combination for the sake of brevity. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (6)
1. The special calcium tablet for perimenopausal women and the preparation method thereof are characterized in that the raw materials are mixed according to the following parts by weight to prepare a beverage: 400-800mg calcium, 5-40 parts of rhizoma polygonati, 5-30 parts of sophora flower, 2-30 parts of wolfberry fruit, 2-30 parts of polygonatum, 2-20 parts of poria cocos, 2-30 parts of chlorella, 5-30 parts of radix puerariae, 5-20 parts of maca and 2-20 parts of broadleaf holly leaf are prepared according to the following method: s1 micronizing radix Puerariae, maca, rhizoma Polygonati Odorati, Poria, and Folum Ilicis, breaking cell wall, and extracting functional components; centrifuging the S2 extract to obtain supernatant; s3 concentrating the supernatant, mixing with calcium material, flos Sophorae Immaturus, fructus Lycii, and Chlorella superfine powder; s4 granulating, aseptically processing, and preparing the special calcium tablet for perimenopausal women by a standard tablet pressing process.
2. The special calcium tablet for perimenopausal women and the preparation method thereof according to claim 1, wherein the stirring leaching parameters are as follows: the liquid-material ratio is 5-12, the extraction temperature is 90-boiling, the extraction time is 0.5-2 hours, and the extraction times are 1-2 times.
3. The special calcium tablet for perimenopausal women and the preparation method thereof according to claim 1, wherein the extract is preferably phosphate solution, the pH value of the extract is maintained to be stable, the ratio of calcium to phosphorus is adjusted to improve the calcium absorption and utilization efficiency.
4. The special calcium tablet for perimenopausal women and the preparation method thereof according to claim 1, wherein the supernatant is obtained by using a continuous centrifugation technology, preferably a tube centrifuge.
5. The special calcium tablet for perimenopausal women according to claim 1, wherein calcium is a calcium-containing raw material prescribed in food safety law, and its preparation method.
6. The special calcium tablet for perimenopausal women prepared by the method and the application thereof in calcium supplement for the perimenopausal women are protected.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010917209.XA CN114129660A (en) | 2020-09-03 | 2020-09-03 | Special calcium tablet for perimenopausal women and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010917209.XA CN114129660A (en) | 2020-09-03 | 2020-09-03 | Special calcium tablet for perimenopausal women and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114129660A true CN114129660A (en) | 2022-03-04 |
Family
ID=80438294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010917209.XA Pending CN114129660A (en) | 2020-09-03 | 2020-09-03 | Special calcium tablet for perimenopausal women and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114129660A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105456711A (en) * | 2014-02-11 | 2016-04-06 | 青岛华之草医药科技有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating postmenopausal osteoporosis |
CN105641370A (en) * | 2014-11-12 | 2016-06-08 | 上海中医药大学附属龙华医院 | Perimenopausal syndrome treating traditional Chinese medicine composition |
-
2020
- 2020-09-03 CN CN202010917209.XA patent/CN114129660A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105456711A (en) * | 2014-02-11 | 2016-04-06 | 青岛华之草医药科技有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating postmenopausal osteoporosis |
CN105641370A (en) * | 2014-11-12 | 2016-06-08 | 上海中医药大学附属龙华医院 | Perimenopausal syndrome treating traditional Chinese medicine composition |
Non-Patent Citations (1)
Title |
---|
陈志霞: "绝经后骨质疏松症的中医药治疗进展", 中医药导报, vol. 13, no. 03, 31 March 2007 (2007-03-31), pages 94 - 96 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100548323C (en) | A kind of pharmaceutical composition of making by Herb Gynostemmae Pentaphylli, Radix Panacis Quinquefolii and the Radix Astragali | |
CN104873624A (en) | Pharmaceutical composition for treating gouty arthritis | |
CN107184892A (en) | Composition with blood-nourishing black hair effect and preparation method thereof | |
CN112826889A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease | |
CN114129660A (en) | Special calcium tablet for perimenopausal women and preparation method thereof | |
CN109541159B (en) | Quality control method and system for obtaining paste quantity of paste | |
CN111494360A (en) | Application of epimedin C in medicine for treating diabetic liver injury | |
CN109908226A (en) | A kind of composition and its preparation and preparation method for improving anaemia | |
CN114128817A (en) | Special auxiliary calcium supplement solid beverage for perimenopausal women and preparation method thereof | |
CN114208984A (en) | Special auxiliary calcium supplement liquid beverage for perimenopausal women and preparation method thereof | |
CN114947127A (en) | Health food composition for improving immunity of tumor patients and preparation method and application thereof | |
CN107029074A (en) | A kind of pharmaceutical composition and preparation method and purposes for treating fatty liver | |
CN104257839B (en) | A kind of Chinese medicine composition with hypoglycemic protection blood vessel endothelium effect and preparation method thereof | |
CN105943713A (en) | Anti-radiation traditional Chinese medicine composition and preparation method thereof | |
CN114129686A (en) | Calcium tablet special for old people and preparation method thereof | |
CN114129662A (en) | Special calcium tablet for pregnant women and preparation method thereof | |
CN105194131A (en) | Traditional Chinese medicine composition for treating osteoporosis and preparation method thereof | |
CN105012507A (en) | Traditional Chinese medicine composition for treating osteoporosis and preparation method of traditional Chinese medicine composition | |
CN114129679A (en) | Calcium tablet special for children and preparation method thereof | |
CN104645080A (en) | Traditional Chinese medicine preparation for treating dizziness and preparation method of traditional Chinese medicine preparation | |
CN110075234A (en) | A kind of antitumor Chinese | |
CN114129681A (en) | Special calcium tablet for lactating women and preparation method thereof | |
CN105998999B (en) | Application of gynecological reconstitution preparation in preparing medicine for preventing and treating tumor and complications thereof | |
CN117180340B (en) | Composition for reducing blood fat and preparation method and application thereof | |
RU2812611C1 (en) | Compositions of ginsenoside rg3 and ginsenoside rg5 and their pharmaceutical uses, including antitumor effects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |